Trials Sponsors Conditions Drugs Pricing

Conditions

Cardiovascular Complication High Blood Pressure

Outcome Measures

Primary Outcomes (3)

Evaluation of blood pressure
Both systolic and diastiolic blood pressure were measured in the office in the seated position, noninvasively.
Before start of chemotherapy (1 hour after including in the trial)
Evaluation of flow-mediated vasodilation and pulse-wave velocity
Flow-mediated dilatation and pulse-wave velocity were measured via "Angioscan" apparatus in the seated position.The cuff inflation period of 5 min was initially decided to produce adequate hyperaemia to allow flow-mediated dilatation. The scanning period used in our trial was 1 minite before and 9 minutes after the cuff deflation.
Before start of chemotherapy (1 hour after including in the trial)
Evaluation of concetration of ENOS and Big Endothelin in blood sampling
Blood was collected from the cubital vein to 10.0 ml/ 6.0 ml red top tubes (without clot activator). The sample was then separated by centrifugation. The serum was frozen to -20C.
Before start of chemotherapy (1 hour after including in the trial)

Secondary Outcomes (3)

Evaluation of blood pressure
In range of 3 -12 weeks after start of chemotherapy (before next chepotherapy drug injection)
Evaluation of flow-mediated vasodilation and pulse-wave velocity
In range of 3 -12 weeks after start of chemotherapy (before next chepotherapy drug injection)
Evaluation of concetration of ENOS and Big Endothelin of blood sampling
In range of 3 -12 weeks after start of chemotherapy (before next chepotherapy drug injection)

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

In this study included 60 patients, that have diagnosis solid cancer of any stage and localisation.All of them is expected to start platinum based or non platinum based chemotherapy.The study proseeds in Chemotherapy department at City Hospital No.1.

You may qualify if:

Subject has solid cancer

Sponsors & Collaborators

I.M. Sechenov First Moscow State Medical University
Otherlead

Study Sites (2)

Olga Andreeva

Moscow, 119421, Russia

First Moscow State Medical University.

Moscow, Russia

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood serum

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Study Officials

Dmitry Shchekochikhin, PhD
I.M. Sechenov First Moscow State Medical University
PRINCIPAL INVESTIGATOR

Enrollment

60 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: OTHER
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

April 18, 2020

First Posted

December 23, 2020

Study Start

January 18, 2018

Actual (reported)

Impact of Platinum-based Cancer Treatment on Endothelial Function

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (3)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (3)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (2)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations